Read more
XTB Online Trading

Massive sell-off in Allakos shares following disappointing clinical trial results for AK006 📉

4:36 PM 27 January 2025

Allakos (ALLK.US) is down more than 77% today after releasing disappointing results from clinical trials of its drug AK006. The drug was intended to treat Chronic Spontaneous Urticaria (CSU), but the phase 1 trial results did not demonstrate sufficient therapeutic activity. As a result, the company has decided to abandon the project, which was one of its leading programs. Following the discontinuation of the project, the company announced it will lay off 75% of its workforce and will begin a review of available strategies to find a new alternative for its future operations.

 

Source: xStation

Share:
Back

Market News

30.04.2025
21:19

Microsoft Beats Expectations in Q3 2025 as Cloud and AI Drive Growth

Microsoft has reported its financial results for the third quarter of fiscal year 2025, significantly surpassing analyst expectations and underscoring...

 18:39

Daily Summary: Wall Street Slides as Economic Data Shows Contraction and Earnings Dissapoint

U.S. stocks tumble as GDP contracts unexpectedly with the US500 falling 1.09%, US30 dropping 0.85%, and US100 sliding 1.19% after data showed the U.S....

 17:12

Oil Prices Hit Four-Year Low at 58 USD

Oil prices have plummeted to their lowest level in four years, with West Texas Intermediate (OIL.WTI) crude dropping more than 19% in April while Brent...
More news

Join over 1 400 000 XTB Group Clients from around the world

Start trading Download the app Download the app
The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits